Alyona Kholodova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alyona Kholodova has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Evgeniya S. Lylova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Kirill Igorevich Kirsanov
Research Institute of Molecular and Cellular Medicine, Peoples’ Friendship University of Russia (RUDN University), 115093 Moscow, Russia
2 shared publications - Marianna G. Yakubovskaya
Research Institute of Molecular and Cellular Medicine, Peoples’ Friendship University of Russia (RUDN University), 115093 Moscow, Russia
2 shared publications A. V. Savinkova
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России
1 shared publicationA. Yu. Portyannikova
ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России
1 shared publication- Aleksandr Kudriashov
Institute of Biomedicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow 117997, Russia
1 shared publication
Latest Publications
- Open Access
- 23 February 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (1) , 14
Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay
Background/Objectives: The aberrant epigenetic landscape of cancer cells has attracted wide attention, motivating the search for new epigenetically active drugs both for anticancer therapy and for overcoming the drug resistance promoted by epigenetic changes. The use of epi-drugs in cancer therapy requires consideration of the influence of applied treatment on epigenetic regulation of gene expression. Therefore, it is reasonable to screen epigenetically active compounds among the drugs widely used in clinical oncology. Methods: We applied the HeLa TI cell-based assay to analyze the epigenetic activity of 40 drugs including 22 chemotherapeutic, 2 immunotherapeutic, 13 targeted, and 3 palliative agents. Reactivation of the epigenetically silenced GFP reporter gene integrated into the genome of HeLa TI cells was assessed using flow cytometry. Results: Statistically significant increases in the proportions of GFP-positive cells were demonstrated for the alkylating agent chlorambucil; the antimetabolites cytarabine, fluorouracil, gemcitabine, and pemetrexed; the platinum-based compounds cisplatin, and oxaliplatin; the topoisomerase inhibitor topotecan; and the antimicrotubule agents docetaxel, vincristine, and eribulin. Epigenetic activity was also detected for the targeted-therapy agents AZD8055, wortmannin, and cetuximab, as well as for the corticosteroid dexamethasone. Thus, epigenetic activity was revealed for 15 drugs widely used in cancer therapy, which possess different modes of action. Conclusions: Our findings show that many anticancer therapy agents modulate the epigenetic landscape of cancer cells, providing a rationale for expanding their therapeutic applications and enhancing the efficacy of combination strategies by overcoming epigenetically driven chemoresistance.
- 23 February 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (1) , 14
Open AccessEpigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay
Background/Objectives: The aberrant epigenetic landscape of cancer cells has attracted wide attention, motivating the search for new epigenetically active drugs both for anticancer therapy and for overcoming the drug resistance promoted by epigenetic changes. The use of epi-drugs in cancer therapy requires consideration of the influence of applied treatment on epigenetic regulation of gene expression. Therefore, it is reasonable to screen epigenetically active compounds among the drugs widely used in clinical oncology. Methods: We applied the HeLa TI cell-based assay to analyze the epigenetic activity of 40 drugs including 22 chemotherapeutic, 2 immunotherapeutic, 13 targeted, and 3 palliative agents. Reactivation of the epigenetically silenced GFP reporter gene integrated into the genome of HeLa TI cells was assessed using flow cytometry. Results: Statistically significant increases in the proportions of GFP-positive cells were demonstrated for the alkylating agent chlorambucil; the antimetabolites cytarabine, fluorouracil, gemcitabine, and pemetrexed; the platinum-based compounds cisplatin, and oxaliplatin; the topoisomerase inhibitor topotecan; and the antimicrotubule agents docetaxel, vincristine, and eribulin. Epigenetic activity was also detected for the targeted-therapy agents AZD8055, wortmannin, and cetuximab, as well as for the corticosteroid dexamethasone. Thus, epigenetic activity was revealed for 15 drugs widely used in cancer therapy, which possess different modes of action. Conclusions: Our findings show that many anticancer therapy agents modulate the epigenetic landscape of cancer cells, providing a rationale for expanding their therapeutic applications and enhancing the efficacy of combination strategies by overcoming epigenetically driven chemoresistance.
- Open Access
- 4 July 2018
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 17 (3) , 77-87
VARIANTS AND PERSPECTIVES OF DRUG REPURPOSING FOR CANCER TREATMENT
Recently many new approaches for repurposing or repositioning of the clinically used drugs have been developed. Drug repurposing allows not only to use known schemes for the synthesis of biologically active compounds, but also to avoid multiple studies that are necessary for drug approval process – analysis of pharmacokinetics, carcinogenicity, acute and chronic toxicity, including cardiotoxicity, nephrotoxicity, allergenicity etc. It makes possible to reduce the number of experimental studies as well as costs of investigations. In cancer research drug repurposing includes screening for medicines used nowadays for the treatment of patients with non-cancer diseases which possess anticancer activity or able to enhance the effects of the standard anticancer chemotherapy, and search for new applications of known anticancer drugs for the treatment of different cancer types. Scientific rationale for the search of the compounds with potential anticancer properties among drugs with different applications is based on the multiple cross-talks of signaling pathways, which can inhibit cell proliferation. Modern advances in genomics, proteomics and bioinformatics, development of permanently improving databases of drug molecular effects and high throughput analytical systems allow researchers to analyze simultaneously a large bulk of existing drugs and specific molecular targets. This review describes the main approaches and resources currently used for the drug repurposing, as well as a number of examples.
- 4 July 2018
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 17 (3) , 77-87
Open AccessVARIANTS AND PERSPECTIVES OF DRUG REPURPOSING FOR CANCER TREATMENT
Recently many new approaches for repurposing or repositioning of the clinically used drugs have been developed. Drug repurposing allows not only to use known schemes for the synthesis of biologically active compounds, but also to avoid multiple studies that are necessary for drug approval process – analysis of pharmacokinetics, carcinogenicity, acute and chronic toxicity, including cardiotoxicity, nephrotoxicity, allergenicity etc. It makes possible to reduce the number of experimental studies as well as costs of investigations. In cancer research drug repurposing includes screening for medicines used nowadays for the treatment of patients with non-cancer diseases which possess anticancer activity or able to enhance the effects of the standard anticancer chemotherapy, and search for new applications of known anticancer drugs for the treatment of different cancer types. Scientific rationale for the search of the compounds with potential anticancer properties among drugs with different applications is based on the multiple cross-talks of signaling pathways, which can inhibit cell proliferation. Modern advances in genomics, proteomics and bioinformatics, development of permanently improving databases of drug molecular effects and high throughput analytical systems allow researchers to analyze simultaneously a large bulk of existing drugs and specific molecular targets. This review describes the main approaches and resources currently used for the drug repurposing, as well as a number of examples.